Cancer Signaling and Experimental Therapeutics Research in the Cancer Signaling and Experimental Therapeutics (CSET) Program focuses cell signaling pathways and how they impact cancer progression and therapy. The overall goal of the members of this program is to elucidate basic signaling mechanisms relevant to tumor biology and apply this knowledge to the discovery and development of new therapeutic approaches. There are two major overiapping themes within the Program's research: The first theme is Cancer Signaling and is comprised of three interrelated research areas;GTPases and kinases, hormonal signaling and cell adhesion signaling. The second theme is Experimental Therapeutics and is comprised of three interrelated research areas;drug delivery and RNA interference, small molecules and clinical trials. Major accomplishments of the Cancer Signaling and Experimental Therapeutics Program over the past funding period include identification of a new therapeutic target in estrogen receptor signaling in breast cancer, advancement of novel isoprenoid anti-cancer compounds into pre-clinical validation studies, and development of RNA-aptamer-based systemic delivery of RNA-interference in prostate cancer. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. For example, within the program Co-leader Dr. Hohl and Dr. Wiemer have collaborated to develop novel isoprenoid compounds with anti-cancer activity and advance these toward clinical trials and Program Leader Dr. Henry shares separate NCI and NIH grant funding with Drs. Quelle and Lynch, Leaders of the Cancer Genetics and Computational Biology and Cancer Epidemiology programs, respectively and has published recently with Dr. Ballas Leader of the Cancer Immunology and Immunotherapy program. The program consists of 45 members from 7 basic science and 8 clinical departments and 3 Colleges. Peer-reviewed, research funding for this program totals $9.8 million with $3.5 million coming from the NCI. Program members published 339 cancer related papers over the prior funding period. Of these publications, 8% were intraprogrammatic, 27% were interprogrammatic and 2% were both intra and interprogrammatic, for a total of 37% collaborative publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-12S1
Application #
8533955
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-03-31
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$3,000
Indirect Cost
$1,013
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Meyerholz, David K; Ofori-Amanfo, Georgina K; Leidinger, Mariah R et al. (2017) Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem 65:607-618
Ebbert, Jon O; Little, Melissa A; Klesges, Robert C et al. (2017) Step Care treatment for smoking cessation. Health Educ Res 32:1-11
Sfeir, J G; Drake, M T; LaPlant, B R et al. (2017) Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 7:e526
Mohiuddin, I; Allen, B G (2017) A Single-Institution Experience in Treating Thymic Carcinoma. Int J Radiat Oncol Biol Phys 98:229
Miller, Benjamin J (2017) CORR Insights®: Is It Appropriate to Treat Sarcoma Metastases With Intramedullary Nailing? Clin Orthop Relat Res 475:218-220
Huang, Jianguo; Chen, Mark; Whitley, Melodi Javid et al. (2017) Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun 8:15999
Jethava, Yogesh S; Barlogie, Bart; Tricot, Guido J (2017) Drug Combinations with Transplantation for Myeloma. N Engl J Med 377:91-2
Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E (2017) Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions. Biol Res Nurs 19:481-490
Rogers, Laura M; Mott, Sarah L; Smith, Brian J et al. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res 23:954-961
Eppsteiner, Robert W; Fowlkes, Jonathan W; Anderson, Carryn M et al. (2017) Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment. Ann Otol Rhinol Laryngol 126:525-529

Showing the most recent 10 out of 831 publications